Edison Issues Report on Percheron Therapeutics (PER)

London, United Kingdom--(Newsfile Corp. - October 7, 2025) - Edison issues report on Percheron Therapeutics (ASX: PER)

Percheron Therapeutics has reported final results from the Phase I dose escalation study of HMBD-002, its monoclonal antibody targeting VISTA, a novel immune checkpoint protein. The data confirmed the compound's favourable safety and tolerability profile (maximum tolerated dose not reached with

Click here to read the full report.

All reports published by Edison are available to download free of charge from its website www.edisongroup.com.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

Connect with Edison on:

LinkedIn www.linkedin.com/company/edison-group-/
X www.x.com/edison_inv_res
YouTube www.youtube.com/edisonitv

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/269438

You May Also Be Interested In

• List of suppliers, parts, photos of iPhone 18 Pro are part of Tata Electronics data breach - Reuters
• Iran's foreign ministry spokesperson: no talks with the U.S. in coming days
• Sea Ltd. (SE) PT Lowered to $162 at Citi